Olivier Brandicourt delivers a keynote speech at the IPlF

BEIJING,March 29,2019 -- Olivier Brandicourt,Chief Executive Officer of Sanofi,delivered a keynote speech at the 2019 International Pharmaceutical Innovation Forum held on March 26th.

Mr. Brandicourtwelcomed China's recent policies and healthcare reforms. "From 2000 to 2016,the Chinese authorities approved around 100 medicines…Just this past year,the NMPA approved 48 medicines,close to the annual standards of the European Medicines Agency or the US FDA. More importantly,behind these figures,there are millions of Chinese patients who now have access to the most innovative medicines in therapeutic areas like oncology,rare diseases and infectious diseases," he said.

Mr. Brandicourtalso spoke highly of China's importance in the international pharmaceutical innovation system. He stressed,"Because the development of innovative medicines has become a global and even more complex endeavor,a fragmented,country-based approach is thus no longer viable…I strongly believe that international cooperation will be a key enabler to advance world-class innovation for Chinese patients in the future."

Regarding the future of China's healthcare system,Mr. Brandicourt put forward five suggestions,including delivering integrated care,leveraging Health Technology Assessment,improving procurement,shifting to primary medical care and prevention,and developing supplementary medical insurance.

The International Pharmaceutical Innovation Forum (IPF) is a Biennial International Conference sponsored by the R&D-based Pharmaceutical Association Committee (RDPAC). Its aim is to create a high-level dialogue and collaboration platform between leaders of China's healthcare innovation ecosystem,in order to accelerate China's world-class innovation and better meet the common needs of global patients. More than 400 people,including government officials,corporate executives,academic experts and NGO representatives,attended this year's forum,calling for joint actions to advance China's world-level innovation to save and improve the lives of patients across the world.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines,provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries,Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi,Empowering Life

About Sanofi China

In 1982,Sanofi opened its first office in China. Sanofi China has a diversified business that ranges from pharmaceuticalsand human vaccines to consumer healthcare. Sanofi's China headquarters in Shanghai are supported by 11 offices in Beijing,Tianjin,Shenyang,Jinan,Hangzhou,Nanjing,Wuhan,Chengdu,Guangzhou,Fuzhou and Urumqi. Sanofi has around 9,600 employees in China.

Sanofi has three manufacturing facilities in China to meet the increasing demand of the domestic market. These plants are located in Beijing,Hangzhou and Shenzhen.

Sanofi operates the China R&D Center and Asia Pacific R&D Hub in Shanghai,Global R&D Operations in Chengdu,and Global Research Institute in Suzhou. Sanofi's R&D focuses on unmet medical needs,such as oncology,immunology,and metabolic diseases in China and the rest of the world.

For more information,please visit www.sanofi.cnor subscribe to the Sanofi China official WeChat account: SanofiChina.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions,statements regarding plans,objectives,intentions and expectations with respect to future financial results,events,operations,services,product development and potential,and statements regarding future performance. Forward-looking statements are generally identified by the words "expects","anticipates","believes","intends","estimates","plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable,investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties,many of which are difficult to predict and generally beyond the control of Sanofi,that could cause actual results and developments to differ materially from those expressed in,or implied or projected by,the forward-looking information and statements. These risks and uncertainties include among other things,the uncertainties inherent in research and development,future clinical data and analysis,including post marketing,decisions by regulatory authorities,such as the FDA or the EMA,regarding whether and when to approve any drug,device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates,the absence of guarantee that the product candidates if approved will be commercially successful,the future approval and commercial success of therapeutic alternatives,the Group's ability to benefit from external growth opportunities,trends in exchange rates and prevailing interest rates,the impact of cost containment policies and subsequent changes thereto,the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi,including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31,2017. Other than as required by applicable law,Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Photo - /20190326/2414533-1-a

Photo - /20190326/2414533-1-b